Synergy
Pharmaceuticals Inc. (Nasdaq: SGYP) reported positive results from a Phase 3
study of its chronic idiopathic constipation treatment plecanatide. The stock price leaped $2.43 to $7.07.
Synergy Pharmaceuticals reports upbeat study results
June 17, 2015 at 12:03 PM EDT
